A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed Non-small Cell Lung Cancer (NSCLC)
Newly Diagnosed, Stage IIIA and Stage IIIB excluding patients with pleural effusion
Patients must have received primary treatment for their disease and had no progression
You may not be if
Diagnosed with NSCLC longer than 6 months ago
Treatment with other bisphosphonates in past 12 months
Presence of metastases
Clareo Health | A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
